Evidence map›Paper›PMID 29987142›Full record

Trial reportAntimicrobial agents and chemotherapy2018

Results of a Multicenter Population Pharmacokinetic Study of Ciprofloxacin in Children with Complicated Urinary Tract Infection.

Kevin Meesters, Robin Michelet, Reiner Mauel, Ann Raes, Jan Van Bocxlaer, Johan Vande Walle, An Vermeulen

Abstract readClinical TrialMulticenter Study
In one paragraph

Trial report in Antimicrobial agents and chemotherapy, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Anti-Microorganisms · 2023
    Review
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Kevin Meesters *Department of Pediatric Nephrology, Ghent University Hospital, Ghent, Belgium kevin.meesters@ugent.be.ORCID 0000-0003-0666-3764
Robin Michelet *Faculty of Pharmaceutical Sciences, Laboratory of Medical Biochemistry and Clinical Analysis, Ghent University, Ghent, Belgium.
Reiner MauelDepartment of Pediatric Nephrology, Ghent University Hospital, Ghent, Belgium.
Ann RaesDepartment of Pediatric Nephrology, Ghent University Hospital, Ghent, Belgium.
Jan Van BocxlaerFaculty of Pharmaceutical Sciences, Laboratory of Medical Biochemistry and Clinical Analysis, Ghent University, Ghent, Belgium.
Johan Vande WalleDepartment of Pediatric Nephrology, Ghent University Hospital, Ghent, Belgium.
An VermeulenFaculty of Pharmaceutical Sciences, Laboratory of Medical Biochemistry and Clinical Analysis, Ghent University, Ghent, Belgium.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Resistance rates for ciprofloxacin, which is labeled for treating complicated urinary tract infections in children, are rapidly rising. As there is limited knowledge on developmental pharmacology of ciprofloxacin, the primary aim of this study was to develop a population pharmacokinetic model for ciprofloxacin in children treated for complicated urinary tract infections. Children to whom ciprofloxacin was prescribed, intravenous (10 to 15 mg/kg body weight every 12 h) or

Indexed as

AdolescentAnti-Bacterial AgentsChildChild, PreschoolCiprofloxacinEnterobacteriaceaeFemaleHumansInfantMaleProspective StudiesPseudomonas aeruginosaStaphylococcus aureusUrinary Tract InfectionsAnti-Bacterial AgentsCiprofloxacinciprofloxacinpediatric pharmacologypopulation pharmacokineticsPseudomonas aeruginosaurinary tract infection

Identifiers

PMID29987142
PMCPMC6125553

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.